Ketorolac Doc Generici (Ketorolac Trometamol)

The drug blocks both cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, preventing the formation of prostaglandins that sensitize pain receptors and promote inflammation. This inhibition reduces peripheral nociceptor activation, delivering rapid pain relief and anti‑inflammatory effects.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s condition, route of administration, and clinical response. Healthcare professionals follow local guidelines and product labeling when selecting an appropriate regimen.

Ketorolac is generally contraindicated in the third trimester of pregnancy because of the risk of fetal complications. Use during earlier trimesters should be limited and only when the potential benefit outweighs the risk. It is excreted in breast milk, so breastfeeding mothers should consult a physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ketorolac offers potent analgesia comparable to some opioids for short‑term use, but it carries a higher risk of renal and gastrointestinal adverse effects than many selective NSAIDs. Unlike opioids, it does not cause respiratory depression or dependence, making it a valuable option for brief, intense pain control when used according to guidelines.

The injectable product must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should not be frozen or shaken. Before administration, inspect the solution for particulate matter and ensure the vial is at the correct temperature to maintain stability.

Ketorolac Doc Generici is supplied for parenteral use and can be given either intramuscularly or intravenously by a qualified healthcare professional. The route, volume, and rate of injection are determined by the prescriber, and the medication should be administered using aseptic technique.

Serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe cardiovascular events such as myocardial infarction or stroke, and life‑threatening hypersensitivity reactions like anaphylaxis. Patients should be monitored closely for signs of these complications, especially when used with other high‑risk medications.

Ketorolac should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, active peptic ulcer disease, severe renal impairment, uncontrolled hypertension, recent coronary artery bypass graft surgery, and in the third trimester of pregnancy. It is also contraindicated in individuals receiving certain anticoagulants without careful risk assessment.